WO2001005434A3 - Hyaluronic acid-protein conjugates - Google Patents
Hyaluronic acid-protein conjugates Download PDFInfo
- Publication number
- WO2001005434A3 WO2001005434A3 PCT/US2000/019803 US0019803W WO0105434A3 WO 2001005434 A3 WO2001005434 A3 WO 2001005434A3 US 0019803 W US0019803 W US 0019803W WO 0105434 A3 WO0105434 A3 WO 0105434A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- protein
- protein conjugates
- present
- synonymous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63579/00A AU6357900A (en) | 1999-07-20 | 2000-07-20 | Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14463999P | 1999-07-20 | 1999-07-20 | |
US60/144,639 | 1999-07-20 | ||
US61906900A | 2000-07-19 | 2000-07-19 | |
US09/619,069 | 2000-07-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001005434A2 WO2001005434A2 (en) | 2001-01-25 |
WO2001005434A3 true WO2001005434A3 (en) | 2001-11-15 |
Family
ID=26842190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/019803 WO2001005434A2 (en) | 1999-07-20 | 2000-07-20 | Hyaluronic acid-protein conjugates |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6357900A (en) |
WO (1) | WO2001005434A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298354B1 (en) * | 2001-10-10 | 2014-03-19 | ratiopharm GmbH | Remodelling and glycoconjugation of interferon-beta |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
CN101724075B (en) * | 2001-10-10 | 2014-04-30 | 诺和诺德公司 | Remodeling and glycoconjugation of peptides |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
TW200612991A (en) | 2004-09-07 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Process for producing water-soluble hyaluronic acid modification |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
PT1835938E (en) | 2004-12-27 | 2013-11-06 | Baxter Int | Polymer-von willebrand factor-conjugates |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP1973952A4 (en) * | 2006-01-23 | 2010-09-01 | Kwangju Inst Sci & Tech | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
US20070225484A1 (en) * | 2006-03-25 | 2007-09-27 | Framroze Bomi P | Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells |
EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
DK2144923T3 (en) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF |
ES2551123T3 (en) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN101965200B (en) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | Conjugated factor VIII molecules |
KR101309566B1 (en) * | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | Hyaluronic acid-protein conjugate, and preparation method thereof |
WO2012118189A1 (en) | 2011-03-03 | 2012-09-07 | 中外製薬株式会社 | Hyaluronic acid derivative modified by amino-carbonic acid |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
KR101658627B1 (en) * | 2012-02-07 | 2016-09-22 | (주)화이바이오메드 | Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same |
RU2674003C2 (en) | 2012-09-05 | 2018-12-04 | Чугаи Сейяку Кабусики Кайся | Hyaluronic acid derivative having amino acid and steryl group introduced therein |
WO2015005459A1 (en) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | Pharmaceutical composition for respiratory administration |
WO2018140220A1 (en) * | 2017-01-27 | 2018-08-02 | Trustees Of Tufts College | Nanocomplexes of polyanion-modified proteins |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0585942A (en) * | 1991-02-26 | 1993-04-06 | Denki Kagaku Kogyo Kk | Interferon-hyaluronic acid and/or its salt combined material |
WO1994001483A1 (en) * | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
US5310881A (en) * | 1990-03-30 | 1994-05-10 | Seikagaku Corporation | Glycosaminoglycan-modified protein |
US5470829A (en) * | 1988-11-17 | 1995-11-28 | Prisell; Per | Pharmaceutical preparation |
WO1997019701A2 (en) * | 1995-11-30 | 1997-06-05 | Hamilton Civic Hospitals Research Development, Inc. | Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates |
US5874417A (en) * | 1993-11-30 | 1999-02-23 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
JP2001081103A (en) * | 1999-09-13 | 2001-03-27 | Denki Kagaku Kogyo Kk | Hyaluronic acid-bound medicinal agent |
-
2000
- 2000-07-20 WO PCT/US2000/019803 patent/WO2001005434A2/en active Application Filing
- 2000-07-20 AU AU63579/00A patent/AU6357900A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470829A (en) * | 1988-11-17 | 1995-11-28 | Prisell; Per | Pharmaceutical preparation |
US5310881A (en) * | 1990-03-30 | 1994-05-10 | Seikagaku Corporation | Glycosaminoglycan-modified protein |
JPH0585942A (en) * | 1991-02-26 | 1993-04-06 | Denki Kagaku Kogyo Kk | Interferon-hyaluronic acid and/or its salt combined material |
WO1994001483A1 (en) * | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
US5874417A (en) * | 1993-11-30 | 1999-02-23 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
WO1997019701A2 (en) * | 1995-11-30 | 1997-06-05 | Hamilton Civic Hospitals Research Development, Inc. | Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates |
JP2001081103A (en) * | 1999-09-13 | 2001-03-27 | Denki Kagaku Kogyo Kk | Hyaluronic acid-bound medicinal agent |
Non-Patent Citations (2)
Title |
---|
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IKETANI, HITOSHI ET AL: "Pharmaceuticals bonded to hyaluronic acid for liver targeting", XP002169036, retrieved from STN Database accession no. 134:242637 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MIMURA, SHUJI ET AL: "Antiviral and anticancer interferon-hyaluronate conjugates with improved blood half-life", XP002169037, retrieved from STN Database accession no. 119:15352 * |
Also Published As
Publication number | Publication date |
---|---|
AU6357900A (en) | 2001-02-05 |
WO2001005434A2 (en) | 2001-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001005434A3 (en) | Hyaluronic acid-protein conjugates | |
AU2926401A (en) | Novel chimeric proteins and methods for using the same | |
AU2001254624A1 (en) | Human coagulation factor vii variants | |
DK1223990T3 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
EP2305822A3 (en) | Methods and compositions for diseases associated with Amyloidosis | |
EP1077070A3 (en) | Oral drug delivery compositions | |
NZ337845A (en) | Non-antigenic branched polymer conjugates | |
FR13C0021I2 (en) | EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE | |
WO1997025052A3 (en) | Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons | |
NL300212I1 (en) | ASP-B28 insulin crystals. | |
WO2001041812A3 (en) | Amphiphilic polymers and polypeptide conjugates comprising same | |
BR0010665A (en) | Erythropoietin Pharmaceutical Compositions | |
WO1996024370B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
DE59407457D1 (en) | BLOCKING THE ADMINISTRATION OF GermS IN HUMAN CELLS | |
WO2002074344A3 (en) | Peg-conjugates of hgt-nk4 | |
AU1122192A (en) | Anti-thrombin polypeptides | |
EP1281763A3 (en) | Early growth response-1 (EGR-1) transcription factor | |
EA200400592A1 (en) | Conjugates Peptide Thymosin α1 and Polymer | |
ATE268181T1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING ALGINATES | |
BR0014803A (en) | Peptide, pharmaceutical composition, use of one or more of the peptides, and diagnostic composition | |
ES2156731A1 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition | |
ATE521635T1 (en) | PHYSIOLOGICALLY EFFECTIVE COMPLEX WITH TNF ACTIVITY | |
JP2916948B2 (en) | Method for stabilizing CPB-I and its pharmaceutical composition | |
DE60223232D1 (en) | MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES | |
JP2001172189A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |